Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer

被引：10

作者：

Kim, Kyu-Sik ^{[1
,2
]}

Oh, In-Jae ^{[1
,2
]}

Ban, Hee-Jung ^{[1
,2
]}

Cho, Hyun-Ju ^{[1
]}

Kwon, Yong-Soo ^{[2
]}

Kim, Yu-Il ^{[2
]}

Lim, Sung-Chul ^{[2
]}

Na, Kook-Joo ^{[1
,3
]}

Song, Sang-Yun ^{[1
,3
]}

Choi, Song ^{[1
,4
]}

Choi, Yoo-Duk ^{[1
,5
]}

Kim, Young-Chul ^{[1
,2
]}

机构：

[1] Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun 519809, Jeonnam, South Korea

[2] Chonnam Natl Univ, Sch Med, Dept Internal Med, Kwangju, South Korea

[3] Chonnam Natl Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Kwangju, South Korea

[4] Chonnam Natl Univ, Sch Med, Dept Radiol, Kwangju, South Korea

[5] Chonnam Natl Univ, Sch Med, Dept Pathol, Kwangju, South Korea

来源：

EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2012年 / 4卷 / 02期

关键词：

non-small cell lung carcinoma; docetaxel; cisplatin; cytochrome P-450; CYP3A5; P-GLYCOPROTEIN; DOCETAXEL; POLYMORPHISMS; CHEMOTHERAPY; EXPRESSION; CISPLATIN; CYP3A5;

D O I：

10.3892/etm.2012.597

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

A combination of docetaxel (D) and cisplatin (P) is one of the standard regimens for the initial treatment of advanced non-small cell lung cancer (NSCLC). Yet, the toxicity of D administered at 75 mg/m(2) in three weekly doses to patients is a concern. The aim of this study was to assess the efficacy of a lower combination dose, 60 mg/m(2) of D and 60 mg/m(2) of cisplatin (P), as a treatment for NSCLC. In this randomized, phase III trial, we compared the response rates (RRs) and toxicity profiles of two combination regimens, D/P 75/60 vs. 60/60 mg/m(2), to patients with stage IIIB or IV NSCLC. A total of 132 patients were randomized to the 75/60 (n=65) or 60/60 (n=67) dosage group. Non-inferiority of 60/60 group compared to the 75/60 group was confirmed by the RR (38.5% for the 75/60 group and 40.3% for the 60/60 group, 95% confidence interval -14.8 to 18.5, meeting the predefined non-inferiority criterion). The dose reduction rate and incidence of grade 3-4 neutropenia were significantly higher in the 75/60 group. The incidence of neutropenia was significantly higher in those with the non-expressing genotype (GG) compared to the AG or AA genotypes of CYP3A5. We determined that DP 60/60 was not inferior to DP 75/60 in RR, and that the reduced combination dosage provides a better safety profile for patients.

引用

页码：317 / 322

页数：6

共 15 条

[1] Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].